Exelixis (EXEL) | Stock Overview & Key Data

What is EXEL's 52-week high and low?

In the last 52 weeks, Exelixis reached a high of $49.62 (on June 23, 2025) and a low of $21.82 (on July 3, 2024).

What is the market cap and P/E ratio for EXEL?

Curious about Exelixis's size and valuation? Its market capitalization stands at 11.83B. When it comes to valuation, the P/E ratio (trailing twelve months) is 19.80, and the forward P/E (looking ahead) is 25.51.

Does EXEL pay dividends? If so, what's the yield?

As for dividends, Exelixis isn't currently offering a significant yield, or that specific data isn't available right now.

Who are Exelixis's main competitors or similar companies to consider before investing?

When looking at Exelixis, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	114.06B	Healthcare	Biotechnology	-3.70%	55.30%
Regeneron REGN	55.27B	Healthcare	Biotechnology	-47.04%	-11.88%
Alnylam ALNY	40.83B	Healthcare	Biotechnology	31.37%	116.26%
Royalty Pharma plc RPRX	20.32B	Healthcare	Biotechnology	40.98%	-15.76%
Insmed INSM	20.02B	Healthcare	Biotechnology	40.34%	296.13%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Exelixis Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Exelixis's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 30.22%, the Debt to Equity ratio from the most recent quarter is 8.78, and its Gross Profit Margin stands at 96.55%.

What is the recent revenue and earnings growth for EXEL?

Looking at Exelixis's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 30.60%, and quarterly earnings saw a YoY growth of 327.70%.

How much of EXEL stock is held by insiders and institutions?

Wondering who owns Exelixis stock? Company insiders (like executives and directors) hold about 2.20% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 94.06%.

For more common questions about our data, please visit our About Data page.